LSV Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$110M Buy
1,410,257
+38,699
+3% +$2.64M 0.2% 153
2026
Q1
$88.6M Buy
1,371,558
+70,503
+5% +$4.97M 0.19% 166
2025
Q4
$87.6M Buy
1,301,055
+35,028
+3% +$2.36M 0.19% 162
2025
Q3
$92.8M Buy
1,266,027
+10,787
+0.9% +$717K 0.21% 149
2025
Q2
$65.3M Buy
1,255,240
+360,049
+40% +$20.5M 0.15% 180
2025
Q1
$57.1M Buy
895,191
+264,130
+42% +$15.3M 0.14% 182
2024
Q4
$30.2M Buy
631,061
+261
+0% +$13.4K 0.07% 267
2024
Q3
$36.1M Buy
630,800
+17,000
+3% +$975K 0.08% 246
2024
Q2
$32.1M Buy
613,800
+152,000
+33% +$6.67M 0.07% 269
2024
Q1
$18.8M Sell
461,800
-600
-0.1% -$22.5K 0.04% 338
2023
Q4
$17.1M Buy
+462,400
New +$17.4M 0.04% 362

Other funds holding HALO

LSV Asset Management's HALO Position: Q2 2026 in Review

LSV Asset Management increased its Halozyme (HALO) stake by 2.8% in Q2 2026, buying an estimated $2.64M and bringing the position to 1,410,257 shares worth $110M. The position accounts for 0.2% of the portfolio, ranked #153.

LSV Asset Management first reported a position in HALO in Q4 2023 and has held it in 11 quarters since. 369 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • LSV Asset Management held 1,410,257 shares of Halozyme worth $110M as of Q2 2026.
  • LSV Asset Management bought 38,699 Halozyme shares in Q2 2026, an estimated $2.64M.
  • Halozyme made up 0.2% of LSV Asset Management's portfolio in Q2 2026, its #153 holding.
  • LSV Asset Management first reported a position in Halozyme in Q4 2023 and has held it in 11 quarters since.
  • 369 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on LSV Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.